Compare RDY & DKNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RDY | DKNG |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 12.4B |
| IPO Year | 2001 | 2021 |
| Metric | RDY | DKNG |
|---|---|---|
| Price | $13.39 | $29.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 31 |
| Target Price | $16.90 | ★ $38.10 |
| AVG Volume (30 Days) | 1.8M | ★ 11.1M |
| Earning Date | 05-12-2026 | 05-07-2026 |
| Dividend Yield | ★ 0.52% | N/A |
| EPS Growth | N/A | ★ 99.05 |
| EPS | N/A | ★ 0.03 |
| Revenue | N/A | ★ $6,054,525,000.00 |
| Revenue This Year | $7.72 | $15.47 |
| Revenue Next Year | $3.50 | $13.09 |
| P/E Ratio | ★ $18.67 | $961.67 |
| Revenue Growth | N/A | ★ 26.99 |
| 52 Week Low | $12.19 | $20.46 |
| 52 Week High | $15.97 | $48.78 |
| Indicator | RDY | DKNG |
|---|---|---|
| Relative Strength Index (RSI) | 50.17 | 71.22 |
| Support Level | $12.86 | $28.30 |
| Resistance Level | $13.95 | $36.46 |
| Average True Range (ATR) | 0.19 | 1.35 |
| MACD | -0.00 | 0.41 |
| Stochastic Oscillator | 46.41 | 95.49 |
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
DraftKings got its start in 2012 as an innovator in daily fantasy sports. Then, following a Supreme Court ruling in 2018 that allowed states to legalize online sports wagering, the company expanded into online sports and casino gambling, where it generally holds the number-two or -three revenue share position across states where it competes. With its predictive market launch in 2025, DraftKings is now live with online or retail sports betting in most all states and i-gaming in five states, with both products available to around 40% of Canada's population. In 2025, sports revenue was 63% of total sales, i-gaming 30%, and fantasy and lottery 7%.